Bria-IMT™ regimen in combination with Incyte’s retifanlimab produced evidence of disease control, tumor shrinkage, and ...
BriaCell has successfully completed its Phase I safety and tolerability evaluation of Bria-IMT™ in combination ...
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 12, 2022 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 28, 2022 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 14, 2022 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 07, 2022 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...
PHILADELPHIA and VANCOUVER, British Columbia, Aug. 04, 2022 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...
Extended survival and tumor shrinkage in advanced breast cancer patients who matched the immunotherapy HLA ...
PHILADELPHIA and VANCOUVER, British Columbia, June 29, 2022 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...
Anti-Cancer activity of BriaCell’s lead candidate, Bria-IMT™, in advanced breast cancer patients was published in ...
Accessibility Tools